Chongqing Taiji Industry Group Co Ltd banner
C

Chongqing Taiji Industry Group Co Ltd
SSE:600129

Watchlist Manager
Chongqing Taiji Industry Group Co Ltd
SSE:600129
Watchlist
Price: 15.51 CNY -0.77%
Market Cap: ¥8.6B

EV/S

1.2
Current
17%
Cheaper
vs 3-y average of 1.5

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
1.2
=
Enterprise Value
¥13.2B
/
Revenue
¥10.5B

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
1.2
=
Enterprise Value
¥13.2B
/
Revenue
¥10.5B

Valuation Scenarios

Chongqing Taiji Industry Group Co Ltd is trading below its 3-year average

If EV/S returns to its 3-Year Average (1.5), the stock would be worth ¥18.71 (21% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+186%
Average Upside
98%
Scenario EV/S Value Implied Price Upside/Downside
Current Multiple 1.2 ¥15.51
0%
3-Year Average 1.5 ¥18.71
+21%
5-Year Average 1.4 ¥17.56
+13%
Industry Average 3.5 ¥44.37
+186%
Country Average 3.3 ¥41.99
+171%

Forward EV/S
Today’s price vs future revenue

Today's Enterprise Value Revenue Forward EV/S
¥13.2B
/
Jan 2026
¥10.5B
=
1.2
Current
¥13.2B
/
Dec 2026
¥12.2B
=
1.1
Forward
¥13.2B
/
Dec 2027
¥13.3B
=
1
Forward
¥13.2B
/
Dec 2028
¥13B
=
1
Forward

Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
EV/S
P/E
All Countries
Close
Market Cap EV/S P/E
CN
Chongqing Taiji Industry Group Co Ltd
SSE:600129
8.6B CNY 1.2 70.9
US
Eli Lilly and Co
NYSE:LLY
825.8B USD 13.2 40
US
Johnson & Johnson
NYSE:JNJ
548.5B USD 6 26.1
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.7 20.1
UK
AstraZeneca PLC
LSE:AZN
215.6B GBP 5.2 27.9
CH
Novartis AG
SIX:NOVN
218.9B CHF 5.2 19.6
US
Merck & Co Inc
NYSE:MRK
272.3B USD 4.7 14.9
IE
Endo International PLC
LSE:0Y5F
244.4B USD 108.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 4.1 11.5
US
Pfizer Inc
NYSE:PFE
150.6B USD 3.2 19.4
US
Bristol-Myers Squibb Co
NYSE:BMY
117.3B USD 3.1 16.6

Market Distribution

Lower than 80% of companies in China
Percentile
20th
Based on 7 593 companies
20th percentile
1.2
Low
0 — 1.7
Typical Range
1.7 — 6.2
High
6.2 —
Distribution Statistics
China
Min 0
30th Percentile 1.7
Median 3.3
70th Percentile 6.2
Max 5 034 353.9

Chongqing Taiji Industry Group Co Ltd
Glance View

Market Cap
8.6B CNY
Industry
Pharmaceuticals

Amidst the sprawling urban landscape of Chongqing, a city often enveloped in a mystical cloak of fog, stands Chongqing Taiji Industry Group Co Ltd., a distinguished entity in the realm of pharmaceuticals. Commanding a legacy that spans over a century, Taiji Industry has mastered the delicate fusion of traditional Chinese medicine with modern pharmaceutical processes. This synthesis has propelled the company to the forefront of China's healthcare sector. The company’s operations revolve around robust research and development, manufacturing, and distribution, focusing on a diverse array of pharmaceutical products, health supplements, and TCM (Traditional Chinese Medicine) remedies. Seamlessly integrating innovation with traditional wisdom, the group has built an extensive portfolio catering to a wide range of medical needs, from cardiovascular treatments to neurological supports. Financially, Taiji Industry's prowess is underpinned by its diverse revenue streams, primarily flowing from its broad spectrum of medicinal drugs and health products. The company has capitalized on its established brand and extensive distribution networks, which span across the vast Chinese landscape and extend their reach into international markets. Their stronghold in distribution is further solidified by strategic collaborations with healthcare providers and retail pharmacy chains, ensuring reliable market penetration and accessibility to the end consumer. This well-oiled machine not only secures Taiji's position as a major pharmaceutical player but also drives its financial growth, allowing the company to invest continuously in innovation, quality enhancement, and market expansion. The synergistic blend of tradition and modernity continues to propel Taiji Industry through the ever-evolving pharmaceutical landscape.

Intrinsic Value
22.89 CNY
Undervaluation 32%
Intrinsic Value
Price ¥15.51
C
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett